1190392-23-4 Usage
Description
Methyl [6(S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-α]]pyrimidine-6-carboxylate is a chemical compound that serves as an intermediate in the synthetic preparation of Vibegron, a potent and selective human β3 adrenergic receptor agonist.
Uses
Used in Pharmaceutical Industry:
Methyl [6(S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-α]]pyrimidine-6-carboxylate is used as a synthetic intermediate for the preparation of Vibegron, a medication for the treatment of overactive bladder. Its role in the synthesis process is crucial for the development of this therapeutic agent, which aims to provide relief to patients suffering from this condition.
Check Digit Verification of cas no
The CAS Registry Mumber 1190392-23-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,0,3,9 and 2 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1190392-23:
(9*1)+(8*1)+(7*9)+(6*0)+(5*3)+(4*9)+(3*2)+(2*2)+(1*3)=144
144 % 10 = 4
So 1190392-23-4 is a valid CAS Registry Number.
1190392-23-4Relevant articles and documents
A process for producing an intermediate agonist GRK 3
-
Paragraph 0144; 0161-0163, (2016/10/10)
The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
-
Page/Page column 50-51, (2012/02/05)
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. (I).
HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
-
Page/Page column 50, (2009/10/30)
The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
